LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel ; Online: Are Behçet's disease patients with Budd-Chiari at increased risk for the development of pulmonary hypertension?

    Ekici, Mustafa / İleri, Serez / Ünaldı, Erdinç / Bayram, Gözde Sevgi Kart / Kılıç, Levent / Akdoğan, Ali

    Rheumatology (Oxford, England)

    2024  

    Sprache Englisch
    Erscheinungsdatum 2024-02-01
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keae067
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 240: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Case report: Pulmonary endarterectomy in Takayasu arteritis patient with group IV pulmonary hypertension: A rare clinical scenario.

    Unaldi, Erdinc / Firlatan, Busra / Duzgun, Selin Ardali / Koca, Suleyman Serdar / Yildizeli, Bedrettin / Akdogan, Ali

    International journal of rheumatic diseases

    2023  Band 27, Heft 3, Seite(n) e15119

    Mesh-Begriff(e) Humans ; Hypertension, Pulmonary/diagnosis ; Hypertension, Pulmonary/etiology ; Hypertension, Pulmonary/surgery ; Takayasu Arteritis/complications ; Takayasu Arteritis/diagnosis ; Takayasu Arteritis/surgery ; Lung ; Diagnosis, Differential
    Sprache Englisch
    Erscheinungsdatum 2023-12-13
    Erscheinungsland England
    Dokumenttyp Case Reports ; Letter
    ZDB-ID 2426924-4
    ISSN 1756-185X ; 1756-1841
    ISSN (online) 1756-185X
    ISSN 1756-1841
    DOI 10.1111/1756-185X.15119
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6098: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Assessing the quality of forced vital capacity measurement in patients with systemic sclerosis.

    Uzun, Güllü Sandal / Sarı, Alper / Karcıoğlu, Oğuz / Sancar, Elif Naz / Unaldı, Erdinç / Fırlatan, Büşra / Bayram, Gözde Sevgi / Kılıç, Levent / Akdoğan, Ali

    Seminars in arthritis and rheumatism

    2024  Band 67, Seite(n) 152466

    Abstract: Introduction: Forced vital capacity (FVC) is an important tool for monitoring lung functions in patients with systemic sclerosis (SSc). However, several disease manifestations may influence the quality of FVC test in SSc. We aimed to assess the quality ... ...

    Abstract Introduction: Forced vital capacity (FVC) is an important tool for monitoring lung functions in patients with systemic sclerosis (SSc). However, several disease manifestations may influence the quality of FVC test in SSc. We aimed to assess the quality of FVC measurements according to current guidelines in patients with SSc and determine the factors that may affect results.
    Method: In this cross-sectional study, SSc patients and age/sex matched controls underwent spirometry. Quality of FVC measurements were graded according to updated American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines. Demographics, clinical features and parameters that may affect FVC test quality were compared between SSc patients with high and low quality FVC test.
    Results: 98 SSc patients (90 female) and 100 controls were included. The rate of high quality FVC measurement in SSc patients was significantly lower in SSc patients compared to controls. (80 % vs 60.2 % p = 0.002). Among SSc patients; diffuse disease, ILD, anti-topoisomerase 1 antibody positivity, immunosuppressive use, flexion contractures of hands, reduced mouth opening and decreased chest expansion were more frequent in patients with low quality FVC (p < 0.05 for all). Patients with muscle weakness and medium/high risk of malnutrition were also numerically higher in low quality FVC group. Presence of more than one condition that may affect FVC quality was significantly higher among patients with low quality FVC.
    Conclusion: A significant percent of SSc patients had low quality FVC measurement. Physicians should be aware of this point while interpreting FVC test results especially in SSc patients with more than one condition that may affect the quality of the test.
    Sprache Englisch
    Erscheinungsdatum 2024-05-20
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 120247-9
    ISSN 1532-866X ; 0049-0172
    ISSN (online) 1532-866X
    ISSN 0049-0172
    DOI 10.1016/j.semarthrit.2024.152466
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 790: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study.

    Bilgin, Emre / Duran, Emine / Ünaldı, Erdinç / Kalyoncu, Umut / Kiraz, Sedat / Ertenli, İhsan

    Rheumatology (Oxford, England)

    2022  Band 61, Heft 9, Seite(n) e267–e269

    Mesh-Begriff(e) Etanercept/adverse effects ; Herpes Zoster/chemically induced ; Herpes Zoster/epidemiology ; Herpesvirus 3, Human ; Humans ; Neoplasms ; Piperidines/adverse effects ; Pyrimidines ; Pyrroles/adverse effects
    Chemische Substanzen Piperidines ; Pyrimidines ; Pyrroles ; tofacitinib (87LA6FU830) ; Etanercept (OP401G7OJC)
    Sprache Englisch
    Erscheinungsdatum 2022-04-08
    Erscheinungsland England
    Dokumenttyp Observational Study ; Letter
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keac226
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 240: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel: Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry.

    Duran, Emine / Ozturk, Zeynep Ozge / Bilgin, Emre / Büyükaşık, Yahya / Dizdar, Omer / Yardimci, Gozde Kubra / Farisogullari, Bayram / Özsoy, Zehra / Ayan, Gizem / Uzun, Gullu Sandal / Ekici, Mustafa / Unaldi, Erdinc / Kilic, Levent / Akdoğan, Ali / Karadag, Omer / Bilgen, Şule Apraş / Kiraz, Sedat / Kalyoncu, Umut / Ertenli, Ali Ihsan

    Rheumatology and therapy

    2023  Band 10, Heft 4, Seite(n) 969–981

    Abstract: Introduction: This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population.: Methods: HUR-BIO ( ... ...

    Abstract Introduction: This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population.
    Methods: HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single-center biological disease-modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA, including rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who had at least one visit after the TNFi were screened from 2005 to November 2021. Standardized incidence rates (SIR) were calculated after adjustment for age and gender and compared with the 2017 Turkish National Cancer Registry (TNCR).
    Results: Of the 6139 patients registered in the HUR-BIO, 5355 used any TNFi at least once. The median follow-up duration was 2.6 years for patients receiving TNFi. Thirteen patients developed a HM on follow-up. In these patients, the median age at the IA onset was 38 (range, 26-67), and the median age at the HM diagnosis was 55.5 (range, 38-76). Patients using TNFi had an increased HM incidence (SIR 4.23, 95% confidence interval (CI) 2.35-7.05). Ten patients with HM were under 65 years of age. In this group, there was a higher incidence of HM in both men (SIR 5.15, 95% CI 1.88-11.43) and women (SIR 4.76, 95% CI 1.74-10.55).
    Conclusions: The risk of HMs in inflammatory arthritis patients receiving TNFi was four times higher than in the general Turkish population.
    Sprache Englisch
    Erscheinungsdatum 2023-06-09
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2783278-8
    ISSN 2198-6584 ; 2198-6576
    ISSN (online) 2198-6584
    ISSN 2198-6576
    DOI 10.1007/s40744-023-00563-z
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality rates.

    Sandal Uzun, Güllü / Taghiyeva, Arzu / Çakır, İbrahim Y / Moral, Kenan / Yardımcı, Gözde Kübra / Bölek, Ertuğrul Ç / Farisoğulları, Bayram / Duran, Emine / Ayan, Gizem / Özsoy, Zehra / Ekici, Mustafa / Unaldı, Erdinç / Germe, Şerife A / Fırlatan, Büşra / Kart-Bayram, Gözde S / Bilgin, Emre / Kılıç, Levent / Karadağ, Ömer / Akdoğan, Ali /
    Bilgen, Şule A / Kiraz, Sedat / Ertenli, Ali Ihsan / Kalyoncu, Umut

    International journal of rheumatic diseases

    2023  Band 27, Heft 1, Seite(n) e14967

    Abstract: Objectives: We aimed to determine the choice of biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/ts-DMARDs), factors associated with the development of chronic kidney disease (CKD), and mortality in RA patients with CKD receiving b/ ... ...

    Abstract Objectives: We aimed to determine the choice of biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/ts-DMARDs), factors associated with the development of chronic kidney disease (CKD), and mortality in RA patients with CKD receiving b/ts-DMARDs.
    Methods: Two thousand one hundred forty-one RA (79.4% female) patients were included in the analysis from the HUR-BIO prospective registry. Patients were divided into the CKD group and the non-CKD group. Age and gender-matched patients were selected from the non-CKD group, and then three main groups were determined. CKD was staged according to the glomerular filtration rate criteria. The clinical characteristics of the patients, disease activities, treatment choices, drug retention rate, and mortality rates were compared between the groups.
    Results: CKD was detected in 90/2141 (4.2%) RA patients on b/ts-DMARDs. Forty patients (2.3%) developed CKD during follow-up after the initiation of b/ts-DMARDs. In the CKD group, anti-TNF agents were chosen as the first-line b/ts-DMARDs therapy in 64.4% of patients, with etanercept leading in 31 (34.4%) patients. In multivariate analysis, age at the start of treatment, DAS-28-ESR at last visit, amyloidosis, hypertension, and history of smoking were the factors associated with the development of CKD in RA patients receiving b/ts-DMARDs. The mortality rate in RA-CKD patients until the onset of the pandemic was 15.41 per 1000 patient years, whereas it was 85.9 per 1000 patient years after the pandemic.
    Conclusion: Comorbidities and control of disease activity are critical in the development of CKD in RA patients receiving b/ts-DMARDs. While there was no significant difference in mortality rate between CKD and non-CKD patients, the overall mortality rate increased after the COVID-19 pandemic duration in both groups.
    Mesh-Begriff(e) Humans ; Female ; Male ; Pandemics ; Tumor Necrosis Factor Inhibitors/adverse effects ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/epidemiology ; Biological Products/adverse effects ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/epidemiology
    Chemische Substanzen Tumor Necrosis Factor Inhibitors ; Antirheumatic Agents ; Biological Products
    Sprache Englisch
    Erscheinungsdatum 2023-12-06
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2426924-4
    ISSN 1756-185X ; 1756-1841
    ISSN (online) 1756-185X
    ISSN 1756-1841
    DOI 10.1111/1756-185X.14967
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6098: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang